We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.16 | 0.36% | 44.10 | 44.47 | 43.728 | 43.87 | 4,632,558 | 16:56:51 |
From May 2019 to May 2024
By Tess Stynes
Bristol-Myers Squibb Co. said its experimental hepatitis C treatment combined with an older drug, ribavirin, and Gilead Sciences Inc.'s Sovaldi cured more than 90% of patients with liver transplants and cirrhosis in a late-stage study.
"Post-liver transplant and cirrhotic patients represent a still-unmet need and continue to present challenges to currently available regimens, " Douglas Manion, Bristol's head of specialty development, said in a news release Monday.
The data, presented at the International Liver Congress, showed 94% of patients that had hepatitis C following a transplant were cured after 12 weeks of treatment, as well as 83% of patients with advanced cirrhosis.
No serious adverse events were reported in the study.
Bristol has been focusing on the hepatitis C treatment--called daclatasvir--in combination with Sovaldi following the U.S. Food and Drug Administration's r ejection of its new drug application in November for daclatasvir in combination with asunaprevir.
Bristol-Myers in October had withdrawn asunaprevir as commercial prospects for the treatment had dimmed based on progress by Gilead and AbbVie Inc.
The FDA in its response letter last year requested additional data about daclatasvir in combination with other antiviral agents.
Daclatasvir in combination with other drugs received approval by European regulators last year. It also has received approvals in Japan and a number of other countries. The FDA is reviewing Bristol's new drug application for daclatasvir and Sovaldi to treat patients with hepatitis C genotype 3.
Bristol shares rose 1.2% to $66.56 in recent premarket trading.
Write to Tess Stynes at tess.stynes@wsj.com
Access Investor Kit for Bristol-Myers Squibb Co.
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US1101221083
Access Investor Kit for Gilead Sciences, Inc.
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US3755581036
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
